Federal Register / Vol. 89, No. 21 / Wednesday, January 31, 2024 / Notices 6119 

year implementation costs and burdens 

that were incurred prior to 2024, it is 

estimated that there will be a decrease 

in total three-year average annual 

burden from 1,684,080 to 668,952. Form 

Number: CMS–10788 (OMB Control 

Number: 0938–1407); Frequency: 

Annually; Affected Public: Private 

Sector; Number of Respondents: 356; 

Number of Responses: 356 Total Annual 

Hours: 668,952. (For policy questions 

regarding this collection contact 

Christina Whitefield at 202–536–8676.) 

Dated: January 25, 2024. 

William N. Parham, III 

Director, Division of Information Collections 

and Regulatory Impacts, Office of Strategic 

Operations and Regulatory Affairs. 

[FR Doc. 2024–01831 Filed 1–30–24; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2024–D–0361] 

Development of Monoclonal Antibody 

Products Targeting SARS–CoV–2 for 

Emergency Use Authorization; 

Guidance for Industry; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice that appeared in the Federal 

Register on December 21, 2023. The 

document announced the availability of 

a final guidance for industry entitled 

‘‘Development of Monoclonal Antibody 

Products Targeting SARS–CoV–2 for 

Emergency Use Authorization.’’ The 

document was published with an 

incorrect docket number. This 

document corrects that error. 

FOR FURTHER INFORMATION CONTACT: 

Maria Clary, Center for Drug Evaluation 

and Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 75, Rm. 4638, Silver Spring, 

MD 20993–0002, 240–402–8615. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of December 21, 2023 

(88 FR 88401), in FR Doc. 2023–28092, 

the following correction is made: 

1. On page 88401, in the first column 

in the header of the document, and in 

the ADDRESSES section, in the second 

and third lines of the first paragraph, the 

Docket No. is corrected to read ‘‘Docket 

No. FDA–2024–D–0361.’’ 

Dated: January 25, 2024. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2024–01836 Filed 1–30–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National 

Institute of Diabetes and Digestive and 

Kidney Diseases Special Emphasis 

Panel NIDDK Application Review: 

RFA–DK–23–017 (U01) and RFA–DK– 

23–018 (U24) Continuation of the 

Childhood Liver Disease Research 

Network (ChiLDReN). 

Date: March 21, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 

6707 Democracy Boulevard, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Cheryl Nordstrom, 

Ph.D., M.Ph., Scientific Review Officer, 

NIDDK/Scientific Review Branch, 

National Institutes of Health, 6707 

Democracy Blvd., Room 7013, Bethesda, 

MD 20892, 301–402–6711, 

cheryl.nordstrom@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: January 25, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01845 Filed 1–30–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK RC2 

Application Review. 

Date: March 1, 2024. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 

20892,(Virtual Meeting). 

Contact Person: Cheryl Nordstrom, Ph.D., 

M.Ph., Scientific Review Officer, NIDDK/ 

Scientific Review Branch, National Institutes 

of Health, 6707 Democracy Blvd., Room 

7013, Bethesda, MD 20892, 301–402–6711, 

cheryl.nordstrom@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: January 25, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01849 Filed 1–30–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 


lotter on DSK11XQN23PROD with NOTICES1